Novo Nordisk: Putting Diabetes on the Global Policy Agenda

By Alexandra Luterek and Vera Oziransky

Type-2 diabetes comprises 90% of people with diabetes around the world, and is largely the result of excess body weight and physical inactivity. The total estimated cost of diagnosed diabetes in the US in 2012 was $245 billion, including $176 billion in direct medical costs and $69 billion in reduced productivity.

Nearly two thirds of the 382 million people worldwide with diabetes also live in cities. If this trend continues, by 2035, as many as half a billion people will have diabetes – nearly all of them in an urban setting. How can policymakers, city planners, and health systems work together to address diabetes as a shared priority – and what is the role of the private sector?

Novo Nordisk, one of the world’s largest producers of diabetes medicines, is creating Shared Value between population health and business profitability to engage cities in reducing their risk for diabetes via cross-sector collaboration.

Read more about how Novo Nordisk is creating Shared Value for Houston, Shanghai, and other cities here. For more on the role of business engagement in community health, read “Beyond the Four Walls: Why Community is Critical to Workforce Health.
Does your organization work with businesses to promote cross sector collaboration for health? We’d love to hear from you, either below or on social media at @VitalityInst and using #Beyond4Walls


Thumbnail image credit: ExploreMetro

Ready to receive the latest in health industry news, tips and trends?

Sign up and we’ll deliver helpful, interesting content right to your inbox.

This field is for validation purposes and should be left unchanged.

Request a demo

Learn how Vitality can help.

This field is for validation purposes and should be left unchanged.